News/ News/ Oncology Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal Phil Taylor immuno-oncology, Jazz Pharmaceuticals, Oncology, partnering, Werewolf Therapeutics 0 Comment Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics Share X Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal https://pharmaphorum.com/news/jazz-adds-first-immuno-oncology-drug-via-1-3bn-werewolf-deal/